| For: | Zacharia GS, Ashraf MH, Sosa F, Jacob A, Patel H. Quick glance at 'metabolic dysfunction associated steatotic liver disease' therapeutics: Targets, trials, and trends. World J Gastrointest Pharmacol Ther 2025; 16(4): 110827 [PMID: 41378068 DOI: 10.4292/wjgpt.v16.i4.110827] |
|---|---|
| URL: | https://www.wjgnet.com/2150-5349/full/v16/i4/110827.htm |
| Number | Citing Articles |
| 1 |
V. V. Gorban, E. V. Gorban, P. E. Kocherga. Non-alcoholic fatty liver disease: Modern approaches to therapy and possibilities of using tirzepatide. Meditsinskiy sovet = Medical Council 2026; (8) doi: 10.21518/ms2026-194
|
| 2 |
Jinguo Wang, Ying Zhang, Shuo Sun, Lanyan Hu, Dong Yang. An updated overview of alkaloids for the prevention and treatment of metabolic dysfunction-associated steatotic liver disease. Frontiers in Pharmacology 2026; 17 doi: 10.3389/fphar.2026.1877634
|
| 3 |
Mario Romeo, Claudio Basile, Andrea Imperatore, Giambattista Mozzi, Fiammetta Di Nardo, Carmine Napolitano, Paolo Vaia, Luigi Di Puorto, Mattia Indipendente, Marcello Dallio, Alessandro Federico. Peroxisome Proliferator-Activated Receptor (PPAR) Agonists in Chronic Liver Diseases: Translating Mechanistic Insights into Clinical Practice and Future Perspectives. Cells 2026; 15(14) doi: 10.3390/cells15141292
|